title: Overview of the safety of felodipine based on clinical trials in patients with hypertension.
abstract: All clinical studies of at least 1 week's duration with felodipine in patients with hypertension were included in a safety analysis. The major finding was that felodipine does not increase mortality or the incidence of major cardiovascular events and that the data indicate a favorable effect.
authors.affiliation: Clinical R&D, Astra Hassle AB, Molndal, Sweden.
authors.forename: L
authors.initials: L
authors.lastname: Welin
authors.forename: L
authors.initials: L
authors.lastname: Elvelin
authors.forename: A
authors.initials: A
authors.lastname: Niklasson
authors.forename: G
authors.initials: G
authors.lastname: Olsson
authors.forename: D
authors.initials: D
authors.lastname: Elmfeldt
mesh_terms: D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000009:adverse effects* / Q000627:therapeutic use; D002561:Cerebrovascular Disorders / Q000453:epidemiology; D004311:Double-Blind Method; D015736:Felodipine / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology; D011358:Product Surveillance, Postmarketing; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic
chemical_list: D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D015736:Felodipine